Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
- PMID: 8100290
- DOI: 10.1016/0140-6736(93)91882-m
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
Abstract
We did a meta-analysis of all published polychemotherapy vs supportive care clinical trials in patients with non-resectable non small cell lung cancer. 7 studies with more than 700 patients were selected. We used the number of deaths at 3, 6, 9, 12, and 18 months as the endpoints because we were unable to obtain all the individual data. Our analysis showed a reduction in mortality during the first 6 months with polychemotherapy. Although small, this increase in survival, together with an improved quality of life, suggests that polychemotherapy should be recommended for patients with non-resectable non small cell lung cancer.
Comment in
-
Is chemotherapy for non-small cell lung cancer worthwhile?Lancet. 1993 Jul 3;342(8862):4. doi: 10.1016/0140-6736(93)91876-n. Lancet. 1993. PMID: 8100297 No abstract available.
-
Polychemotherapy in advanced non-small-cell lung cancer.Lancet. 1993 Sep 18;342(8873):740-1; author reply 741-2. Lancet. 1993. PMID: 8103839 No abstract available.
-
Polychemotherapy in advanced non-small-cell lung cancer.Lancet. 1993 Sep 18;342(8873):741; author reply 741-2. Lancet. 1993. PMID: 8103840 No abstract available.
-
Polychemotherapy in advanced non-small-cell lung cancer.Lancet. 1993 Sep 18;342(8873):741; author reply 741-2. Lancet. 1993. PMID: 8103841 No abstract available.
-
Polychemotherapy in advanced non-small-cell lung cancer.Lancet. 1993 Sep 18;342(8873):741; author reply 741-2. Lancet. 1993. PMID: 8103842 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
